Seminars in Nuclear Medicine
Volume 39, Issue 5 , Pages 308-340 , September 2009

Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions

  • Dominique Delbeke, MD, PhD

      Affiliations

    • Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN
    • Corresponding Author InformationAddress reprint requests to: Dominique Delbeke, MD, PhD, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 21st Avenue South and Garland, Nashville, TN 37232-2675
    • ,
  • Heiko Schöder, MD

      Affiliations

    • Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • William H. Martin, MD

      Affiliations

    • Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Richard L. Wahl, MD

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology and Oncology, Johns Hopkins University, School of Medicine, Baltimore, MD

References 

  1. Gambhir SS, Czernin J, Schimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S
  2. Wahl RL, Quint LE, Cieslak RD, et al. Tumor imaging: Fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med. 1993;34:1190–1197
  3. Koral KF, Zasadny KR, Kessler ML, et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131 monoclonal antibody therapy of lymphoma patients. J Nucl Med. 1994;35:1714–1720
  4. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in the evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–1209
  5. Roman CD, Martin WH, Delbeke D. Incremental value of fusion imaging with integrated PET-CT in oncology. Clin Nucl Med. 2005;30:470–477
  6. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–2161
  7. Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44:1413–1420
  8. Khafif A, Schneebaum S, Fliss DM, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma. Head Neck. 2006;28:874–879
  9. Schoder H, Yeung HW, Gonen M, et al. Head and neck cancer: Clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65–72
  10. Fleming AJ, Smith SP, Paul CM, et al. Impact of PET/CT on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–1179
  11. Gordin A, Golz A, Keidar Z, et al. The role of FDG-PET/CT imaging in head and neck malignancies—Impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg. 2007;137:130–137
  12. Gordin A, Golz A, Daitzchman M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: Diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys. 2007;68:370–376
  13. Lerman H, Metser U, Lievshitz G, et al. Lymphoscintigraphic sentinel node identification in patients with breast cancer: The role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33:329–337
  14. van der Ploeg IM, Valdes Olmos RA, Nieweg OE, et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48:1756–1760
  15. Lerman H, Lievshitz G, Zak O, et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48:201–206
  16. Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107:2545–2551
  17. Heron DE, Beriwal S, Avril N. FDG-PET and PET/CT in radiation therapy simulation and management of patients who have primary and recurrent breast cancer. PET Clin. 2006;1:39–49
  18. Bar-Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005;32:918–924
  19. Wong WL, Chambers RJ: Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastrooesophageal cancer: A literature review. Abdom Imaging 33:183-190
  20. Soyka JD, Veit-Haibach P, Strobel K, et al. Staging pathways in recurrent colorectal carcinoma: Is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med. 2008;49:354–361
  21. Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69:155–162
  22. Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–1151
  23. Park JY, Kim EN, Kim DY, et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: Evaluation of 88 patients. Int J Gynecol Cancer. 2008;18:1332–1338
  24. Chung HH, Kang WJ, Kim JW, et al. The clinical impact of [18 F]FDG PET/CT for the management of recurrent endometrial cancer: Correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging. 2008;35:1081–1088
  25. Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271–276
  26. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658–666
  27. Chung HH, Kang WJ, Kim JW. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: Correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480–486
  28. Soussan M, Wartski M, Cherel P. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008;108:160–165
  29. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: Comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1439–1448
  30. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–1442
  31. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177–1182
  32. Serra A, Bolasco P, Satta L, et al. Role of SPECT/CT in the preoperative assessment of hyperparathyroid patients. Radiol Med. 2006;111:999–1008
  33. Krausz Y, Bettman L, Guralnik L, et al. Tc99m-MIBI SPECT/CT in primary hyperparathyroidism. World J Surg. 2006;30:76–83
  34. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with In111-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol. 2003;59:565–573
  35. Pfannenberg AC, Eschmann SM, Horger M, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835–843
  36. Hillel PG, van Beek EJ, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumors. Clin Radiol. 2006;61:579–587
  37. Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin's lymphoma patients in the PET/CT era?. Ann Oncol. 2006;17:117–122
  38. Tateishi U, Yamaguchi U, Seki K, et al. Bone and soft-tissue sarcoma: Preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 2007;245:839–847
  39. Filippi L, Schillaci O. Usefulness of hybrid SPECT/CT in 99mTc-HMPAO-labeled leukocyte scintigraphy for bone and joint infections. J Nucl Med. 2006;47:1908–1913
  40. Ciernik IF, Dizendorf E, Ciernik IF, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiation Biol Phys. 2003;57:853–863
  41. Coleman RE, Delbeke D, Guiberteau MJ, et al. Intersociety dialogue on Concurrent PET-CT with an integrated imaging system: From the Joint ACR/SNM/SCBT-MR PET-CT Working Group. J Nucl Med. 2005;46:1225–1239
  42. Schreve P. PET/CT. Semin Ultrasound CT MRI. 2008;29:283–289
  43. Delbeke D, Coleman RE, Guiberteau MJ, et al. Society of Nuclear Medicine procedure guidelines for tumor imaging using FDG PET/CT. J Nucl Med. 2006;47:885–895
  44. Delbeke D, Coleman RE, Guiberteau MJ, et al. Society of Nuclear Medicine procedure guidelines for SPECT/CT imaging. J Nucl Med. 2006;47:1227–1234
  45. MacManus MP, Hicks RJ. Where do we draw the line? (Contouring tumors on positron emission tomography/computed tomography). Int J Radiat Oncol Biol Phys. 2008;71:2–4
  46. Schillaci O, Filippi L, Manni C, et al. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47
  47. Pirotte BJ, Lubansu A, Massager N, et al. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg. 2007;107:392–399
  48. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–1298
  49. Pirotte B, Goldman S, Van Bogaert P, et al. Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery. 2005;57(suppl):128–139
  50. Pichler BJ, Wehrl HF, Kolb A, et al. Positron emission tomography/magnetic resonance imaging: The next generation of multimodality imaging?. Semin Nucl Med. 2008;38:199–208
  51. McGuirt WF, Greven K, Williams D, et al. PET scanning in head and neck oncology: a review. Head Neck. 1998;20:208–215
  52. Lowe VJ, Boyd JH, Dunphy FR. Surveillance for recurrent head and neck cancer using PET. J Clin Oncol. 2000;18:651–658
  53. Blodgett TM, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck: Part 1. Physiologic, altered physiologic, and artefactual FDG uptake. Radiographics. 2005;25:897–912
  54. Uchida Y, Minoshima S, Kawata T, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med. 2005;30:170–176
  55. Branstetter BF IV, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone?. Radiology. 2005;235:580–586
  56. Shah J. Cervical lymph node metastases: Diagnostic, therapeutic and prognostic implications. Oncology. 1990;4:61–69
  57. Schoder H, Carlson DL, Kraus DH, et al. FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med. 2006;47:755–762
  58. Tenkos T, Rosenthal E, Lee D, et al. Positron emission tomography in evaluation of stage III and IV head and neck cancer. Head Neck. 2001;23:1056–1060
  59. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301–1314
  60. Wartski M, Le Stanc E, Vilain D, et al. In search of unknown primary tumor presenting with cervical metastases: Performance of hybrid FDG-PET-CT. Nucl Med Commun. 2007;28:365–371
  61. Zimmer LA, Branstetter BF, Nayak JV, et al. Current use of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115:2029–2034
  62. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with head and neck cancer using FDG PET. Head Neck. 1997;19:666–674
  63. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of 18F-FDG-PET with conventional imaging modalities (MRI, CT and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med. 2003;44:198–206
  64. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175–181
  65. Ong SC, Schöder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532–540
  66. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer—A Long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9–14
  67. Brouwer J, Bodar EJ, De Bree R, et al. Detecting recurrent laryngeal carcinoma after radiotherapy: Room for improvement. Eur Arch Otorhin. 2004;261:417–422
  68. Gordin A, Daitzchman M, Doweck I, et al. FDG PET/CT imaging in patients with carcinoma of the larynx: Diagnostic accuracy and impact on clinical management. Laryngoscope. 2006;116:273–278
  69. Wang D, Schultz CJ, Jursinic PA, et al. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:143–151
  70. Zheng XK, Chen LH, Wang QS, et al. Influence of [18F] fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:1020–1025
  71. Koshy M, Paulino AC, Howell R, et al. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck. 2005;27:494–502
  72. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2008;70:678–684
  73. Silvestri GA, Gould MK, Margolis ML. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd ed). Chest. 2007;132:178S–201S
  74. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicenter randomised trial. Lancet. 2002;359:1388–1393
  75. Lardinois D, Weder W, Hany TF, et al. Staging of non–small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  76. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51–60
  77. Deniaud-Alexandre E, Touboul E, Lerouge D, et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1432–1441
  78. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339–350
  79. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78–86
  80. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  81. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol. 2001;19:111–118
  82. Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:187–195
  83. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  84. Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis. Int J Radiat Oncol Biol Phys. 2006;64:435–448
  85. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1016–1023
  86. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. Int J Radiat Oncol Biol Phys. 2005;62:70–75
  87. van der Hoeven JJ, Hoekstra OS, Comans EF, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002;236:619–624
  88. Wilking N, Rutqvist LE, Cartensen J, et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol. 1992;31:29–35
  89. Lim HS, Yoon W, Chung TW, et al. FDG PET/CT for the detection and evaluation of breast diseases: Usefulness and limitations. Radiographics. 2007;27:S197–S213
  90. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–S229
  91. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-d-glucose. J Natl Cancer Inst. 1996;88:1204–1209
  92. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27:407–410
  93. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105–112
  94. Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol. 2004;183:479–486
  95. Yap CS, Seltzer MA, Schiepers C, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: The referring physician's perspective. J Nucl Med. 2001;42:1334–1337
  96. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004;31:932–939
  97. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imag Biol. 2005;7:369–376
  98. Tatsumi M, Cohade C, Mourtzikos KA, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33:254–262
  99. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and skeletal metastases. Semin Nucl Med. 2005;35:135–142
  100. Du Y, Cullum I, Illidge TM, et al. Fusion of metabolic function and morphology: Sequential [18F]-fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of skeletal metastases in breast cancer. J Clin Oncol. 2007;25:3440–3447
  101. Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189–196
  102. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–278
  103. Bruzzi JF, Munden RF, Truong MT, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27:1635–1652
  104. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–3210
  105. Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg. 2002;74:1026–1032
  106. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255–1259
  107. Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109:125–134
  108. Das A, Chak A. Reassessment of patients with esophageal cancer after neoadjuvant therapy. Endoscopy. 2006;381:S13–S17
  109. Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol. 2006;78:254–261
  110. Zhong X, Yu J, Zhang B, et al. Using (18)F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73:136–141
  111. Drudi FM, Trippa F, Cascone F, et al. Esophagogram and CT vs endoscopic and surgical specimens in the diagnosis of esophageal carcinoma. Radiol Med (Torino). 2002;103:344–352
  112. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumors: Long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153–162
  113. Basu S, Mohandas KM, Peshwe H, et al. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nucl Med Commun. 2008;29:1026–1039
  114. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of colorectal cancer. J Nucl Med. 2000;41:1177–1189
  115. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology. 2002;224:748–756
  116. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—Meta-analysis. Radiology. 2005;237:123–1231
  117. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–511
  118. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]-fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388–395
  119. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18-fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–447discussion:447-450
  120. Cohade C, Osman M, Leal J, et al. Direct comparison of FDG PET and PET-CT imaging in colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  121. Tateishi U, Maeda T, Morimoto T, et al. Non-enhanced CT vs. contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:1627–1634
  122. Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007;6:31–36
  123. Ciernik IF, Huser M, Burger C, et al. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:893–900
  124. Wudel LJ, Delbeke D, Morris D, et al. The role of FDG-PET imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117–126
  125. Ho CL, Shen S, Young DWC, et al. Dual tracer PET/CT in the evaluation of hepatocellular carcinoma. J Nucl Med. 2007;48:902–909
  126. Anderson CA, Rice MH, Pinson CW, et al. FDG PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90–97
  127. Kim YJ, Yun M, Lee WJ, et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinomas. Eur J Nucl Med Mol Imaging. 2003;30:1467–1472
  128. Moon CM, Bang S, Chung JB, et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol. 2008;23:759–765
  129. Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206:57–65
  130. Delbeke D, Rose M, Chapman WC, et al. Optimal interpretation of F-18FDG imaging of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784–1792
  131. Buck AK, Nekolla S, Ziegler S, et al. SPECT/CT. J Nucl Med. 2008;49:1305–1319
  132. Schillaci O, Filippi L, Danieli R, et al. Single-photon emission computed tomography/computed tomography in abdominal diseases. Semin Nucl Med. 2007;37:48–61
  133. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: Findings at state-of-the-art MR imaging, US, CT and pathologic analysis. Radiographics. 2004;24:3–17
  134. Brancatell G, Vilgrain V, Zappa M, et al. Case 80: Splenosis. Radiology. 2005;234:1225–1229
  135. Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy (I.A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group). Cancer. 1991;67:2776–2785
  136. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745–3749
  137. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET. Radiology. 2001;218:776–782
  138. Tran BN, Grigsby PW, Dehdashti F, et al. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol. 2003;90:572–576
  139. Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005;97:183–191
  140. Lin LL, Mutic S, Low DA, et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys. 2007;67:91–96
  141. Boughanim M, Leboulleux S, Rey A, et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol. 2008;26:2558–2561
  142. Esthappan J, Chaudhari S, Santanam L, et al. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive Para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2008;72:1134–1139
  143. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol. 2000;77:454–459
  144. Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310–315
  145. Bristow RE, del CMG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90:519–528
  146. Bosniak MA. The current radiographic approaches to renal cysts. Radiology. 1986;158:1–10
  147. Russo P. Renal cell carcinoma: Presentation, staging, and surgical treatment. Semin Oncol. 2000;27:160–176
  148. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  149. Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–1809
  150. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol. 2007;304–310
  151. Schöder H, Herrmann K, Gönen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761–4769
  152. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32–38
  153. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398
  154. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555
  155. Nuñez R, Macapinlac HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46–55
  156. Wong TZ, Turkington TG, Polascik TJ, et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005;184:676–680
  157. Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007;37:17–28
  158. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721
  159. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–297
  160. Hain SF, O'Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000;27:590–594
  161. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-2-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034–1039
  162. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol. 1996;14:1637–1641
  163. Flechon A, Bompas E, Biron P, et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol. 2002;168:1975–1979
  164. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42:998–1004
  165. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985–1994
  166. Pryma DA, Schöder H, Gönen M, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006;47:1260–1266
  167. Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501–507
  168. Koopmans KP, de Groot JW, Plukker JT, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation. J Nucl Med. 2008;49:524–531
  169. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study. Eur J Nucl Med. 1999;26:1547–1552
  170. Wang W, Macapinlac H, Finn RD, et al. PET scanning with [18F] 2-fluoro2 deoxy-d-glucose (FDG) can localize residual differentiated thyroid cancer in patients with negative [131I]-iodine whole-body scans. J Clin Endocrinol Metab. 1999;84:2291–2302
  171. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–1113
  172. Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009;94:1310–1316
  173. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616–624
  174. Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res. 2005;25:1421–1426
  175. Salvatori M, Melis L, Castaldi P, et al. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed Pharmacother. 2007;61:488–493
  176. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:112–121
  177. Krenning EP. Somatostatin receptor scintigraphy. In:  Sandler MP,  Patton JA,  Coleman RE, et al. editor. Diagnostic Nuclear Medicine. (3rd ed.). Philadelphia: Lippincott; 1996;p. 735–746
  178. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  179. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–1626
  180. Baum R, Niesen A, Leonhardi J, et al. Receptor PET/CT imaging of neuroendocrine tumours using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3 octreotide (DOTA-NOC): Clinical results in 327 patients. Eur J Nucl Med Mol Imaging. 2005;32(suppl 1):S54–S55
  181. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: Nuclear medicine's view. J Pharm Pharm Sci. 2007;10:321s–337s
  182. Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med. 2004;29:86–90
  183. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: Correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727–734
  184. Rozovsky K, Koplewitz BZ, Krausz Y, et al. The added value of SPECT/CT for the correlation of MIBG scan and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol. 2008;190:1085–1090
  185. Tang HR, Da Silva AJ, Matthay KK, et al. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med. 2001;42:237–247
  186. Shulkin BL, Hutchinson RJ, Castle VP, et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–750
  187. Kushner BH, Yeung HW, Larson SM, et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397–3405
  188. Lavely WC, Goetze S, Friedman KP, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007;48:1084–1089
  189. Nichols KJ, Tomas MB, Tronco GG, et al. Preoperative parathyroid scintigraphic lesion localization: Accuracy of various types of readings. Radiology. 2008;248:221–232
  190. Lu P. Staging and classification of lymphoma. Semin Nucl Med. 2005;35:160–164
  191. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643–4651
  192. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med. 2005;35:165–175
  193. Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–329
  194. Rodríguez-Vigil B, Gómez-León N, Pinilla I, et al. PET/CT in lymphoma: Prospective study of enhanced full-dose PET/CT vs. unenhanced low-dose PET/CT. J Nucl Med. 2006;47:1643–1648
  195. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  196. Alazraki N, Glass EC, Castronovo F, et al. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness, version 1.0. http://interactive.snm.org/docs/pg_ch24_0403.pdf2002;
  197. Belhocine TZ, Scott AM, Evan-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med. 2006;47:957–967
  198. Garbe C, Paul A, Kohler-Späth H. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–529
  199. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: State of the art 2006. Melanoma Res. 2007;17:117–127
  200. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000;44:153–167
  201. Bastiaannet E, Oyen WJG, Meijer S, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93:243–249
  202. Strobel K, Dummer R, Husarik D, et al. High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244:566–674
  203. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–1187
  204. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–1367
  205. Römer W, Nömayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47:1102–1106
  206. Horger M, Eschmann SM, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR. 2004;183:655–661
  207. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–271
  208. Strobel K, Burger C, Seifert B, et al. Characterization of focal bone lesions in the axial skeleton: Performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188:W467–W474
  209. Kostakoglu L, Hardoff R, Mirtcheva R, et al. PET/CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411–1431
  210. Metser U, Lerman H, Blank A, et al. Malignant involvement of the spine: Assessment by 18F-FDG PET/CT. J Nucl Med. 2004;45:279–284
  211. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imag. 2005;32:1253–1258
  212. Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19:573–579
  213. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73–92
  214. Israel O, Goldberg A, Nachtigal A, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280–1284
  215. Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36:286–294
  216. McDonald M, Cooper R, Wang MY. Use of computed tomography-single-photon emission computed tomography fusion for diagnosing painful facet arthropathy (Technical note). Neurosurg Focus. 2007;22:E2
  217. Even-Sapir E, Flusser G, Lerman H, et al. SPECT/multislice low-dose CT: A clinically relevant constituent in the imaging algorithm of non-oncologic patients referred for BS. J Nucl Med. 2007;48:319–324
  218. Ovadia D, Metser U, Lievshitz G, et al. Back pain in adolescents: Assessment with integrated 18F-fluoride positron-emission tomography-computed tomography. J Pediatr Orthop. 2007;27:90–93
  219. Lim R, Fahey FH, Drubach LA, et al. Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain. J Pediatr Orthop. 2007;27:277–282
  220. Even-Sapir E, Mishani E, Flusser G, et al. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–469
  221. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, non-physiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): Accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37:206–222
  222. Horger M, Eschmann SM, Pfannenberg C, et al. Added value of SPECT/CT in patients suspected of having bone infection: Preliminary results. Arch Orthop Trauma Surg. 2007;127:211–221
  223. Bar-Shalom R, Yefremov N, Guralnik L, et al. SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. J Nucl Med. 2006;47:587–594
  224. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics. 2005;25:1357–1368
  225. Hartmann A, Eid K, Dora C, et al. Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging. 2007;34:704–714
  226. Keidar Z, Militianu D, Melamed E, et al. The diabetic foot: Initial experience with 18F-FDG PET/CT. J Nucl Med. 2005;46:444–449
  227. Mahfouz T, Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: A study of 165 infectious episodes. J Clin Oncol. 2005;23:7857–7863
  228. Keidar Z, Engel A, Hoffman A, et al. Prosthetic vascular graft infection: The role of 18F-FDG-PET/CT. J Nucl Med. 2007;48:1230–1236

PII: S0001-2998(09)00015-4

doi: 10.1053/j.semnuclmed.2009.03.002

Seminars in Nuclear Medicine
Volume 39, Issue 5 , Pages 308-340 , September 2009

Article Tools

* Image Usage & Resolution